High Potency Apis /Hpapi Market- Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

High Potency Apis /Hpapi Market- Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The high-potency APIs/HPAPI market is projected to register a CAGR of 8.5% during the forecast period (2022-2027).

During the COVID-19 pandemic, the high-potency APIs/HPAPI market was adversely affected. The COVID-19 outbreak primarily affected the supply chain of the API market. Since Southeast Asia (specifically China and India) is the hub for the production of API, the market was severely hampered as COVID-19 increased in the region. According to the Germany Trade & Invest (GTAI) article titled "Covid-19 Fuels Debate over API Production Locations" published in April 2020, around 60% of APIs, including high-potency APIs of the world, are manufactured in India or China. India alone accounts for 18% of the global generic drug manufacturing market, most of which is exported to other countries. China is a major manufacturing location and produces 70% of the APIs, including high-potency APIs, for India's generics industry. This situation makes these two countries the biggest players in the global market for generic medicines. However, these countries were the most affected by the pandemic. As the virus spread globally, India temporarily placed an export curb on 26 drugs and various high-potent APIs, which accounted for around 10% of the country's pharmaceutical exports, to avoid domestic shortages. This factor further fueled the adversity in the market. However, various APIs are used in the production of COVID-19 vaccines. Overall, the market was considered to be hindered in the short term. However, the market may grow significantly once the industry reinforces its supply chain with modern advancements and protocols.

Certain factors driving the market’s growth include increasing demand for drugs (oncology and antibody-drug conjugates), increasing focus on precision medicine and high potency APIs, and technological advancements in high-potency API manufacturing. The International Agency for Research on Cancer (IARC) updated GLOBOCAN 2020 with new estimates about the global cancer burden, indicating that the cancer burden rose to 19.3 million cases and 10 million cancer deaths in 2020. This new study suggests that more than 50 million people will be diagnosed with cancer within five years. The use of high potency APIs in various drug therapies are also adding to the market growth. For instance, United States Center for Drug Evaluation and Research (CDER) approved new therapies in 2020 for various cancers, particularly lung, thyroid, and breast cancers. These therapies included small and large API molecules for treatments. High-potency APIs are the primary constituents of these drugs. With the growing number of cancer cases, the market will simultaneously grow to provide solutions for the disease. Similarly, according to Parkinson’s Foundation's article published in July 2020, around 60,000 Americans are diagnosed with Parkinson's disease each year. There has been a focus on precision medicine in the past few years. The need for personalized medicine with higher efficacy is increasing. These generic drugs are known as pharmacogenetics. In 2020, the US Food and Drug Administration listed information relating to 200 pharmacogenetic drugs. In United Kingdom, the National Health Scheme aims to integrate genomic medicines into its routine care by 2025. Therefore, owing to the increase in the research on the precision medicine and the utilization of high potency APIs for drug development, the studied market is estimated to witness a healthy growth rate during the forecast period.

The high-potency APIs/HPAPI market is broadly segmented into innovative high-potency active pharmaceutical ingredients and generic high-potency active pharmaceutical ingredients. The primary factor for the growth is the patent expiration of various drugs and increasing demand for cancer treatment, along with the huge number of cancer treatment drugs in the pipeline for the future. According to the report published by the American Journal of Managed Care in June 2021, by 2023, patents of around 20 oncology biologics will expire, which may lead to the production of more biosimilars in cancer care and reduce costs. Due to these reasons, the market may see a high growth rate during the forecast period.

Also, the government initiatives focusing on active pharmaceutical ingredient production are adding to the growth of the studied market. In June 2021, the Indian Finance Minister announced an additional outlay of INR 197,000 crore for utilization over five years for the pharmaceutical Production Linked Incentive (PLI) Scheme in 13 key sectors such as active pharmaceutical ingredients, drug intermediaries, and key starting materials. The large incentives being allocated to the active pharmaceutical ingredient segment would greatly boost the market growth over the forecast period.​

Several key market players are also adding to the growth of the market over the forecast period. For instance, in April 2021, Pfizer acquired Amplyx Pharmaceuticals Inc., a privately-held company dedicated to developing therapies. The company makes several drugs, such as Fosmanogepix (a fungal inhibitor), which require high-potency APIs to manufacture. Such acquisitions are expected to boost the growth of the market over the forecast period.

North America is expected to hold a significant share in the market during the forecast period

United States was the most affected country in the world, with the prevalence of disorders such as cancer and neurological disorders. These disorders are increasing in prevalence, thus increasing the production of HPAPIs in the region. HPAPIs are widely used in many therapeutic, drug discovery, or other research studies related to oncology and other major disorders. Thus, the demand for the same will be significantly higher in the North American region as the patient population is increasing compared to other countries.

North America is expected to hold a major share in the high-potency APIs/HPAPI market due to the rising geriatric population and increasing prevalence and incidence of infectious diseases in this region. The incidence of chronic diseases, like cancer, is also high in United States. As per the 2020 report by the American Cancer Society journal, there were an estimated 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in 2020. According to the 2020 data by Parkinson’s Foundation, around 1 million people in United States are living with Parkinson's disease, more than the combined number of people diagnosed with muscular dystrophy, multiple sclerosis, and Amyotrophic Lateral Sclerosis. This number is expected to increase to 1.2 million by 2030.

According to GLOBOCAN 2020, in Canada, around 225,800 new cancer cases and 83,300 cancer deaths were recorded in the year 2020. Around 30% of all deaths in Canada are caused by cancer. However, Canada has a universal healthcare system for its citizens. This factor creates an even demand in the region. Due to this factor, the market may register positive growth during the forecast period.

Moreover, the increasing R&D activities and the presence of favorable healthcare infrastructure are fueling the growth of the overall regional market. ​

The high-potency APIs/HPAPI market is fragmented, competitive, and consists of several major players. In terms of market share, a few major players are currently dominating the market, including Thermo Fisher Scientific Inc., Merck KGaA, Pfizer, Novartis International AG, and Teva Pharmaceutical Industries.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support